Charles River and Eisai sign research deal

15 February 2016

Scientists fromUSA-based contract research organization Charles River Laboratories (NYSE: CRL) are to work at Japanese pharma major Eisai's (TYO: 4523) research and development facilities in the UK, under a new collaboration agreement.

The move will involve Charles River supporting Eisai scientists from Japan, the USA and the UK on a range of synthetic and medicinal chemistry projects, including those seeking novel treatments for neurological diseases.

Charles River scientists will also participate in a medicinal chemistry project to discover new antimalarial drugs with activity against drug resistant strains of disease, which could potentially address this area of unmet medical need in malaria treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK